Content about Proteobacteria

September 4, 2013

Aptalis Pharma has launched its 10-day drug therapy for treating a gastrointestinal bacterial infection and ulcer condition, the company said.

BRIDGEWATER, N.J. — Aptalis Pharma has launched its 10-day drug therapy for treating a gastrointestinal bacterial infection and ulcer condition, the company said.

Aptalis announced the launch of Pylera 10 Day Therapy PAK (bismuth subcitrate potassium; metronidazole; tetracycline hydrochloride). The drug is approved for use in combination with the proton-pump inhibitor omeprazole in patients with Helicobacter pylori infection and duodenal ulcer disease that is either active or has a history of occurring within the past five years, for eradicating H. pylori.

August 2, 2013

The Food and Drug Administration has approved a vaccine against meningococcal disease for use among patients of a broader age range than before.

CAMBRIDGE, Mass. — The Food and Drug Administration has approved a vaccine against meningococcal disease for use among patients of a broader age range than before.

December 11, 2012

Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

EXTON, Pa. — Biotech and vaccines company Nuron Biotech has bought rights from Pfizer for a vaccine to prevent infection by a bacteria that is a major cause of infectious disease around the world.

June 15, 2012

GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.

PHILADELPHIA — GlaxoSmithKline has received regulatory approval from the Food and Drug Administration for a vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type B.

MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid conjugate vaccine) is approved for use in children ages six weeks through 18 months. The vaccination schedule is a four-dose series given at two, four, six, and 12 through 15 months of age.

March 14, 2012

A bacterium found in the stomach may be associated with diabetes, according to a study published in the Journal of Infectious Diseases.

NEW YORK — A bacterium found in the stomach may be associated with diabetes, according to a study published in the Journal of Infectious Diseases.

April 25, 2011

The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first vaccine for preventing meningococcal disease in children as young as 9 months old, the agency said.

The FDA announced the approval of Menactra, made by Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis. Meningococcal disease is a life-threatening illness caused by Neisseria meningitidis bacteria that infect the bloodstream and the lining surrounding the brain and spinal cord.

February 1, 2011

The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

BASEL, Switzerland — The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

Novartis announced the approval of Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197 conjugate vaccine) for active immunization to prevent certain forms of meningococcal disease caused by Neisseria meningitidis in children ages 2 to 10 years. The FDA approved the vaccine last year for use in adolescents and adults ages 11 to 55 years.

October 25, 2010

An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in...

BASEL, Switzerland An investigative vaccine made by Novartis appears to offer good protection against meningococcal disease in infants, according to results of a late-stage clinical trial released Monday.

 

The Swiss drug maker said results of a phase-3 trial showed that Menveo (meningococcal group A, C, W135 and Y) induced immune responses in a high percentage of babies against four strains of the bacteria. Meningococcal disease occurs suddenly and can cause serious illness and often death during the first year of life.

 

 

February 21, 2010

Novartis has received Food and Drug Administration approval for a vaccine for meningococcal disease, the...

CAMBRIDGE, Mass. Novartis has received Food and Drug Administration approval for a vaccine for meningococcal disease, the Swiss drug maker’s vaccines division announced Monday.

The FDA approved Menveo (meningococcal [groups A, C, Y and W-135] oligosaccharide diphtheria CRM197) to prevent meningococcal disease caused by Neisseria meningitidis bacteria.

 

January 3, 2010

Helicobacter pylori, an infection that causes gastric ulcers and cancers of the gut, may be...